AwesomeCapital
Tuesday, November 5, 2019
Blueprint Medicines EPS beats by $0.26, beats on revenue
Blueprint Medicines (NASDAQ:
BPMC
): Q3 GAAP EPS of -$1.93
beats by $0.26
.
Revenue of $9.14M (+730.9% Y/Y)
beats by $6.29M
.
Press Release
https://seekingalpha.com/news/3514315-blueprint-medicines-and-nbsp-eps-beats-0_26-beats-revenue
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
‹
›
Home
View web version
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.